Literature DB >> 11931415

sICAM-1 as a serum marker in the diagnosis and follow-up of treatment of pulmonary tuberculosis.

T Demir1, C Yalçinoz, I Keskinel, F Demiröz, N Yildirim.   

Abstract

OBJECTIVE: To detect the value of sICAM-1 in the diagnosis and follow-up of treatment of tuberculosis.
DESIGN: sICAM-1 levels were evaluated before and after treatment in 30 patients with pulmonary tuberculosis, only before treatment in five patients with pneumonia, five with lung cancer, and five with bronchiectasis, and in 10 healthy volunteers.
RESULTS: sICAM-1 levels were as follows: 436.2 +/- 194.4 ng/ml in patients with pulmonary tuberculosis, 274 +/- 32.1 ng/ml in lung cancer patients, 268 +/- 41.9 ng/ml in bronchiectasis patients, 199.6 +/- 43.1 ng/ml in pneumonia patients, and 146.5 +/- 20.2 ng/ml in healthy individuals. sICAM-1 levels of tuberculosis cases before treatment were higher than in both the healthy group and in all the other groups. The levels in the healthy group were lower than in all other groups.
CONCLUSION: The cut-off point (298 ng/ml) obtained by adding the standard deviation to the mean sICAM-1 value of patients without tuberculosis had 83.3% sensitivity, 86.6% specificity and 84.4% accuracy in differentiating pulmonary tuberculosis from other pulmonary diseases. sICAM-1 can be used as an auxiliary marker in the diagnosis of pulmonary tuberculosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11931415

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  5 in total

Review 1.  Immunological biomarkers of tuberculosis.

Authors:  Gerhard Walzl; Katharina Ronacher; Willem Hanekom; Thomas J Scriba; Alimuddin Zumla
Journal:  Nat Rev Immunol       Date:  2011-04-08       Impact factor: 53.106

2.  Effect of standard tuberculosis treatment on plasma cytokine levels in patients with active pulmonary tuberculosis.

Authors:  Catherine Riou; Blas Perez Peixoto; Lindi Roberts; Katharina Ronacher; Gerhard Walzl; Claudia Manca; Roxana Rustomjee; Thuli Mthiyane; Dorothy Fallows; Clive M Gray; Gilla Kaplan
Journal:  PLoS One       Date:  2012-05-14       Impact factor: 3.240

3.  Plasma Biomarkers of Risk of Tuberculosis Recurrence in HIV Co-Infected Patients From South Africa.

Authors:  Kimesha Pillay; Lara Lewis; Santhuri Rambaran; Nonhlanhla Yende-Zuma; Derseree Archary; Santhanalakshmi Gengiah; Dhineshree Govender; Razia Hassan-Moosa; Natasha Samsunder; Salim S Abdool Karim; Lyle R McKinnon; Nesri Padayatchi; Kogieleum Naidoo; Aida Sivro
Journal:  Front Immunol       Date:  2021-03-25       Impact factor: 7.561

4.  Is analysis of inflammatory biomarkers and lymphocyte subpopulations useful in prediction of tuberculosis treatment outcomes?

Authors:  Greta Musteikienė; Skaidrius Miliauskas; Jurgita Zaveckienė; Daiva Urbonienė; Astra Vitkauskienė; Marius Žemaitis; Albinas Naudžiūnas
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2021-09-08

5.  Plasma heme oxygenase-1 levels distinguish latent or successfully treated human tuberculosis from active disease.

Authors:  Bruno B Andrade; Nathella Pavan Kumar; Katrin D Mayer-Barber; Daniel L Barber; Rathinam Sridhar; Vaithilingam V Banu Rekha; Mohideen S Jawahar; Thomas B Nutman; Alan Sher; Subash Babu
Journal:  PLoS One       Date:  2013-05-06       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.